{"prompt": "['Product: MK-3475', '10', 'Protocol/Amendment No.: 604-09', 'LIST OF FIGURES', 'Figure 1', 'Trial Design Overview', '19', 'Figure 2', 'Imaging and Treatment for Clinically Stable Subjects After First', 'Radiologic Evidence of PD Assessed by the Site', '83', 'Figure 3', 'Multiplicity Graph for Type I Error Control', '111', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '11', 'Protocol/Amendment No.: 604-09', 'DOCUMENT HISTORY', 'Document', 'Date of Issue', 'Overall Rationale', 'Original protocol', '15 DEC-2016', 'Amendment 01', '21-DEC-2016', 'Corrected a typographical error in the numbering of the inclusion criteria so', 'that the structure of the trial database and the electronic data capture forms can', 'be created correctly.', 'Amendment 02', '23-FEB-2017', 'Corrected the wording of exclusion criterion #5, which stated the opposite of', 'what was intended and to provide more detail and clarity where needed.', 'Amendment 03', '10-APR-2017', 'Removed the option to cross over from the etoposide/platinum/saline placebo', 'arm to pembrolizumab treatment to improve the interpretation of the long-term', 'benefit.', 'Amendment 04', '02-JUN-2017', 'Removed the requirement for unblinding treatment assignment after', 'documentation of progressive disease (PD) because the option to cross over to', 'pembrolizumab was removed and, with it, the need to unblind.', 'Amendment 05', '01-SEP-2017', 'Clarified exclusion criterion #4 regarding brain metastases to ensure that no', 'subjects with brain metastases are enrolled in the study.', 'Amendment 06', '30-NOV-2017', 'Updated the dose modification guidelines for pembrolizumab to include', 'information regarding the treatment of myocarditis; revised the requirements', 'for survival follow-up to allow for more frequent data collection; added a', 'Day 8 visit during Cycles 1 through 4 to allow for more frequent safety', 'monitoring.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '12', 'Protocol/Amendment No.: 604-09', 'Document', 'Date of Issue', 'Overall Rationale', 'Amendment 07', '03-OCT-2018', '; changed the alpha allocation', 'between the primary (overall survival [OS] and PFS) and key secondary', '(objective response rate [ORR]) hypothesis on the basis of accumulating', 'external data on PFS and os in immunotherapy-chemotherapy combinations', 'in small cell lung cancer to allow more alpha to be allocated to the primary', 'endpoints.', 'Amendment 08', '07-DEC-2018', 'the assumption for median PFS in the', 'control arm was changed to 4.3 months based on external data published from', 'other clinical trials; and the power and efficacy bound calculations were', 'updated to reflect the change in PFS median assumption and an alpha spending', 'approach.', 'Amendment 09', '23-APR-2019', 'Updated criteria for the final os analysis to be a minimum of 294 events, or 31', 'months from study start, whichever occurs later to ensure sufficient follow-up', 'time for the final os analysis. Added clarification to describe the alpha-', 'spending strategy for PFS and OS in detail. Corrected a publishing error in', 'Amendment 08.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}